Cargando…
Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania
Leishmania species are causative agents of human leishmaniasis, affecting 12 million people annually. Drugs available for leishmaniasis are toxic, and no vaccine is available. Thus, the major thrust is to identify new therapeutic targets. Leishmania is an auxotroph for heme and must acquire heme fro...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143042/ https://www.ncbi.nlm.nih.gov/pubmed/35631106 http://dx.doi.org/10.3390/pathogens11050585 |
_version_ | 1784715707831812096 |
---|---|
author | Ansari, Irshad Basak, Rituparna Mukhopadhyay, Amitabha |
author_facet | Ansari, Irshad Basak, Rituparna Mukhopadhyay, Amitabha |
author_sort | Ansari, Irshad |
collection | PubMed |
description | Leishmania species are causative agents of human leishmaniasis, affecting 12 million people annually. Drugs available for leishmaniasis are toxic, and no vaccine is available. Thus, the major thrust is to identify new therapeutic targets. Leishmania is an auxotroph for heme and must acquire heme from the host for its survival. Thus, the major focus has been to understand the heme acquisition process by the parasites in the last few decades. It is conceivable that the parasite is possibly obtaining heme from host hemoprotein, as free heme is not available in the host. Current understanding indicates that Leishmania internalizes hemoglobin (Hb) through a specific receptor by a clathrin-mediated endocytic process and targets it to the parasite lysosomes via the Rab5 and Rab7 regulated endocytic pathway, where it is degraded to generate intracellular heme that is used by the parasite. Subsequently, intra-lysosomal heme is initially transported to the cytosol and is finally delivered to the mitochondria via different heme transporters. Studies using different null mutant parasites showed that these receptors and transporters are essential for the survival of the parasite. Thus, the heme acquisition process in Leishmania may be exploited for the development of novel therapeutics. |
format | Online Article Text |
id | pubmed-9143042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91430422022-05-29 Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania Ansari, Irshad Basak, Rituparna Mukhopadhyay, Amitabha Pathogens Review Leishmania species are causative agents of human leishmaniasis, affecting 12 million people annually. Drugs available for leishmaniasis are toxic, and no vaccine is available. Thus, the major thrust is to identify new therapeutic targets. Leishmania is an auxotroph for heme and must acquire heme from the host for its survival. Thus, the major focus has been to understand the heme acquisition process by the parasites in the last few decades. It is conceivable that the parasite is possibly obtaining heme from host hemoprotein, as free heme is not available in the host. Current understanding indicates that Leishmania internalizes hemoglobin (Hb) through a specific receptor by a clathrin-mediated endocytic process and targets it to the parasite lysosomes via the Rab5 and Rab7 regulated endocytic pathway, where it is degraded to generate intracellular heme that is used by the parasite. Subsequently, intra-lysosomal heme is initially transported to the cytosol and is finally delivered to the mitochondria via different heme transporters. Studies using different null mutant parasites showed that these receptors and transporters are essential for the survival of the parasite. Thus, the heme acquisition process in Leishmania may be exploited for the development of novel therapeutics. MDPI 2022-05-16 /pmc/articles/PMC9143042/ /pubmed/35631106 http://dx.doi.org/10.3390/pathogens11050585 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ansari, Irshad Basak, Rituparna Mukhopadhyay, Amitabha Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania |
title | Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania |
title_full | Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania |
title_fullStr | Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania |
title_full_unstemmed | Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania |
title_short | Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania |
title_sort | hemoglobin endocytosis and intracellular trafficking: a novel way of heme acquisition by leishmania |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143042/ https://www.ncbi.nlm.nih.gov/pubmed/35631106 http://dx.doi.org/10.3390/pathogens11050585 |
work_keys_str_mv | AT ansariirshad hemoglobinendocytosisandintracellulartraffickinganovelwayofhemeacquisitionbyleishmania AT basakrituparna hemoglobinendocytosisandintracellulartraffickinganovelwayofhemeacquisitionbyleishmania AT mukhopadhyayamitabha hemoglobinendocytosisandintracellulartraffickinganovelwayofhemeacquisitionbyleishmania |